OBJECTIVE： To compare the economics of albumin-bound paclitaxel vs. solvent-based paclitaxel in the treatment of metastatic breast cancer （MBC）， and provide reference for clinical treatment decision making. METHODS： Medical records of 15 MBC patients receiving albumin-bound paclitaxel or solvent-based paclitaxel respectively were selected from HIS during Jan. 2011 to May 2015， including 72， 74 chemotherapy cycles. Using every 2 consecutive cycles of chemotherapy as a measure point， cost data and the results of clinical efficacy evaluation were collected. Objective remission rate and the incidence of ADR were calculated， and pharmacoeconomic analysis was conducted. RESULTS： Compared with solvent-based paclitaxel， objective remission rate of was albumin-bound paclitaxel was higher， without statistical significance （47.22％ vs. 37.84％， P＞0.05）； there was no statistical significance in the number of ADR cases （19 cases vs. 16 cases， P＞0.05）； cost-minimization analysis could be used to study the economics of them. The cost of albumin-bound paclitaxel was higher than that of solvent-based paclitaxel （37 404.82 yuan vs. 17 049.02 yuan）， which was supported by sensitivity anlysis. CONCLUSIONS： Therapeutic efficacy of albumin-bound paclitaxel is slightly better than that of solvent-based paclitaxel， but the latter has pharmacoeconomic advantage. The drugs should be selected according to the condition of patients.